Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy

Journal of Medical Virology

Volumn 79, Issue 7, 2007, Pages 902-910

  U, Im Chang ^a   Young, Chun Lee ^a   Seong, Heon Wie ^a   Jeong, Won Jang ^a   Si, Hyun Bae ^a   Jong, Young Choi ^a   Jin, Mo Yang ^a   Seung, Kew Yoon ^a   Hee, Sik Sun ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Breakthrough hepatitis; Core promoter; Drug resistance; Hepatitis B virus; Precore; Reverse transcriptase

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ASPARTIC ACID; DNA POLYMERASE; LAMIVUDINE; METHIONINE; TYROSINE; VIRUS DNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DNA DETERMINATION; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GENE SEQUENCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTANT; VIRUS REPLICATION; VIRUS RESISTANCE; WILD TYPE;

ADENINE; ADULT; ANTIVIRAL AGENTS; BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; FEMALE; GENE PRODUCTS, POL; GENES, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PROMOTER REGIONS (GENETICS); VIRAL CORE PROTEINS; VIREMIA;

HEPATITIS B VIRUS;

EID: 34249940912     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20819     Document Type: Article

References (28)

1. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670-1677.
2. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Dolledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S. 2003. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125:292-297.
3. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H. 1998. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27:1711-1716.
4. Cho SW, Hahm KB, Kim JH. 2000. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 32:1163-1169.
5. Ciancio A, Smedile A, Rizzetto M, Lagget M, Gerin J, Korba B. 2004. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy. Hepatology 39:64-73.
6. Fang ZL, Yang J, Ge X, Zhuang H, Gong J, Li R, Ling R, Harrison TJ. 2002. Core promoter mutations (A(1762)T and G(1764)A) and viral genotype in chronic hepatitis B and hepatocellular carcinoma in Guangxi, China. J Med Virol 68:33-40.
7. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL, Adefovir Dipivoxil 438 Study Group. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348:800-807.
8. Kao JH, Chen PJ, Lai MY, Chen DS. 2002. Sequence analysis of pre-S/ surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection. J Med Virol 68:216-220.
9. Kim SS, Chung MG, Ju KT, Park DK, Kwon OS, Koo YS, Kim YK, Choi DJ, Hwang YJ, Kim JH. 2002. Clinical and virologic characteristics of lamivudine resistance in HBV-associated chronic liver disease. Taehan Kan Hakhoe Chi 8:405-417. Korean.
10. Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, Wong BC, Dent J, Wu PC. 1997. Lamvudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial. Hepatology 25:241-244.
11. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN. 2001. On behalf of the Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 33:1527-1532.
12. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. 1999. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30:567-572.
13. Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, Benardi M, Andreone P. 2000. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 32:1145-1153.
14. Loriot M, Marcellin P, Talbodec N, Guigonis V, Gigou M, Boyer N, Bezeaud A, Erlinger S, Benhamou JP. 1995. Low frequency of precore hepatitis B virus mutants in anti-hepatitis B e-positive reactivation after loss of hepatitis B e antigen in patients with chronic hepatitis B. Hepatology 21:627-631.
15. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J. Brosgart CL, Adefovir Dipivoxil 437 Study Group. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348:808-816.
16. Naito H, Hayashi S, Abe K. 2001. Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers. J Clin Microbiol 39:362-364.
17. Nicoli AJ, Colledge DL, Toole JJ, Angus PW, Smallwood RA, Locarnini SA. 1998. Inhibition of duck hepatitis B virus replication by 9-(2- phosphonylmethoxyethyl) adenine, an acyclic phosphonate nucleoside analogue. Antimicrob Agents Chemother 42: 3130-3135.
18. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, MaDade H. 1996. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 93:4398-4402.
19. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, Tanaka T, Miyakawa Y, Mayumi M. 1994. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 68:8102-8110.
20. Peri-ilio R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A. 2000. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32:129-134.
21. Suzuki F, Kumada H, Nakamura H. 2006. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy. J Med Virol 78:1025-1034.
22. Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, Gibbs CS, Parvaz P, Werle B, Trepo C, Zoulim F. 2003. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 39:1085-1089.
23. Werle B, Cinquin K, Marcellin P, Pol S, Maynard M, Trepo C, Zoulim F. 2004. Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy. J Viral Hepat 11:74-83.
24. Westland CE, Yang H, Delaney WE 4th, Gibbs CS, Miller MD, Wulfsohn M, Fry J, Brogsgart CL, Xion S. 437 and 438 Study Teams. 2003. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 38:96-103.
25. Yang H, Westland CE, Delanev WE 4th, Heathcote EJ, Ho V, Fry J, Brosgart C, Gibbs CS, Miller MD, Xiong S. 2002. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 36:464-473.
26. Yeh CT, Chien RN, Chu CM, Liaw YF. 2000. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 31:1318-1326.
27. Yoon SK, Jang JW, Kim CW, Bae SH, Choi JY, Choi SW, Lee YS, Lee CD, Chung KW, Sun HS, Kim BS. 2005. Long-term results of amivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: Response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology 48:341-349.
28. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. 2001. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34:785-791.